# DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026

- Link: https://www.thailand-business-news.com/pr-news/deepqure-reports-encouraging-clinical-data-from-worlds-first-extravascular-rdn-system-at-aua-2026
- Published: 2026-05-15T01:30:00+07:00
- Author: PR Newswire

WASHINGTON, May 15, 2026 /PRNewswire/ — DeepQure, a clinical-stage medical device
company, announced the completion of its featured presentation at the American Urological
Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure
was selected to present the clinical progress of HyperQure™, the world’s first minimally
invasive (laparoscopic/robotic) extravascular renal denervation (RDN) system.

The Innovation Nexus Forum is a premier platform for featuring cutting-edge urological
technologies. DeepQure was invited to present its unique approach to treating uncontrolled
hypertension, which addresses the inherent limitations of conventional catheter 
based intravascular RDN to address anatomical diversity and achieve full denervation.

While conventional intravascular RDN systems are now commercially available, variable
blood pressure reduction due to incomplete or inconsistent nerve ablation remains
as a significant unmet challenge. HyperQure™ is engineered to address this inherent
limitation by enabling direct, circumferential ablation of perivascular nerves from
outside the artery, independent of vessel anatomy.

**Expanding Global Clinical Momentum**

During the forum, DeepQure reported clinical milestones across its international
programs:

 ◦ Clinical Status: Successfully completed 15 cases in two early-phase studies —
   Korea’s first-in-human trial and the US Early Feasibility Study (IDE).
 ◦ Institutional Participation: US clinical trials are currently conducted at leading
   academic centers, including Stanford University, Mayo Clinic, Emory University,
   UC Irvine, University of Florida, and Henry Ford Health System.
 ◦ KOL Participation: DeepQure’s network of global authorities in hypertension includes
   Drs. David Kandzari and Herbert Aronow, recently bolstered by Professor Raymond
   Townsend (Medtronic’s SPYRAL HTN lead investigator) to ensure clinical integrity
   for upcoming trials.
 ◦ Safety Profile: No device-related major adverse events (MAEs) have been reported.
   All patients are in the follow-up stage, with full clinical data scheduled to
   be presented at EuroPCR 2026 in May.

"The AUA Innovation Nexus Forum provided a critical stage to demonstrate how our
extravascular, circumferential approach addresses the therapeutic gap in current
RDN treatments," said Chanho Park, Chairman of the Board of DeepQure. "With 15 cases
completed across Korea and the US, the company is now focused on advancing its global
pivotal trial."

**About the AUA Innovation Nexus Forum**

The AUA Innovation Nexus Forum provides a collaborative venue for showcasing emerging
technologies and transformative innovations in urology. The forum connects medical
device innovators with global clinical experts to accelerate the development of 
solutions that address significant unmet needs in urological and related healthcare
fields.

**About Uncontrolled Hypertension and RDN**

Uncontrolled hypertension affects an estimated ~30% of hypertensive patients globally
and is associated with a significantly elevated risk of stroke and heart failure.
It is clinically defined as systolic blood pressure that remains above 140mmHg despite
pharmacological treatment. RDN is an interventional therapy designed to lower blood
pressure by disrupting overactive sympathetic nerves surrounding the renal arteries.

**About DeepQure**

DeepQure is a clinical-stage medtech company developing next-generation RDN treatments.
Its lead product, HyperQure™, is a proprietary extravascular system designed for
360° circumferential ablation of renal nerves from outside the vessel. HyperQure
holds the Korean MFDS Breakthrough Device Designation and ISO 13485 certification.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026 ](http://www.prnasia.com/story/archive/4959520_CN59520_0?rand=184833)